### [Hutchins et al. Page 1298][1] Keytruda® pembrolizumab is an approved treatment for multiple cancer indications. Given the clinical impact of pembrolizumab and the continuing research to improve PD-1-related immunotherapies, better understanding of the molecule's preclinical characterization

中文翻译：

---

本期精选文章

### [Hutchins等。Page 1298] [1]Keytruda®pembrolizumab是一种批准用于多种癌症适应症的治疗方法。鉴于pembrolizumab的临床影响以及改善PD-1相关免疫疗法的持续研究，人们对该分子的临床前表征有了更好的了解